Whole‐genome sequencing analysis of Japanese autism spectrum disorder trios
Characterizing the comprehensive genetic architecture and phenotypes of ASD is a fundamental step towards unraveling its complex biology.
Authors
- Hidekazu Kato (ORCID: https://orcid.org/0000-0001-9995-504X)
- Maeri Yamamoto (ORCID: https://orcid.org/0000-0002-5239-6225)
- Tomoo Ogi (ORCID: https://orcid.org/0000-0002-5492-9072)
- Norio Ozaki (ORCID: https://orcid.org/0000-0002-7360-4898)
- Masahiro Banno (ORCID: https://orcid.org/0000-0002-2539-1031)
- Itaru Kushima (ORCID: https://orcid.org/0000-0002-0018-5178)
- Yutaka Nagasaki
- Yoshihiro Nawa (ORCID: https://orcid.org/0000-0003-3164-2519)
- Hiroki Kimura (ORCID: https://orcid.org/0000-0002-0610-7904)
- Branko Aleksić (ORCID: https://orcid.org/0000-0001-8982-4580)
- Sawako Furukawa (ORCID: https://orcid.org/0000-0003-2558-5853)
- Mariko Uematsu
Institutions
- Nagoya University Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1111/pcn.13767
- Citations
- 4
- Primary Topic
- Autism Spectrum Disorder Research
- Type
- article
- Field-Weighted Citation Impact
- 1.37
Funders
- Eli Lilly and Company
- GlaxoSmithKline
- Takeda Pharmaceutical Company
- Uehara Memorial Foundation
- Japan Agency for Medical Research and Development
- EA Pharma Co., Ltd.
- Nihon Medi-Physics
- GlaxoSmithKline Japan
- Boehringer Ingelheim Japan
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
- Eisai
- Meiji Seika Pharma
- Shionogi
- Hori Sciences and Arts Foundation
- SENSHIN Medical Research Foundation
- Ono Pharmaceutical
- H. Lundbeck A/S
- Novartis Pharma
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe